Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Completed 19Active not recruiting 13Recruiting 11Terminated 7Unknown 3Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 3

Interventions

Cisplatin 509Cyclophosphamide 360Carboplatin 352Radiotherapy 350Capecitabine 329Paclitaxel 325Oxaliplatin 324Gemcitabine 319Docetaxel 311Fluorouracil 284Drug Therapy 244apatinib 242Bevacizumab 230camrelizumab 214Etoposide 200Irinotecan 177Doxorubicin 175Leucovorin 162Dexamethasone 160sintilimab 142pembrolizumab 140anlotinib 136Pemetrexed 136Cytarabine 136toripalimab 129Neoadjuvant Therapy 122S 1 (combination) 120Vincristine 119Rituximab 117Radiosurgery 117

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × Interventional × luprolide acetate gel depot × Clear all
NCT04239599 2022-09-29

RCT-PHART2

Sunnybrook Health Sciences Centre

Phase NA Unknown
178 enrolled
Genitourinary

Prostatic Neoplasms

NCT03380806 2020-06-04

PBS

Juravinski Cancer Center

Phase 2 Unknown
100 enrolled
Genitourinary

Prostatic Neoplasms

NCT00452556 2014-03-19

The ELDORADO (Eligard®, Docetaxel and Radiotherapy) Study

Nova Scotia Cancer Centre

Phase 2 Unknown
86 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡